Boston Scientific Shares Sink as Soft Guidance Overshadows Q4 Beat

The Marlborough, Massachusetts-based company reported fourth-quarter net income of $672 million, or 45 cents per share, marking a significant climb from $562 million during the same period last year. On an adjusted basis, earnings reached 80 cents per share, narrowly beating the 78-cent average estimate from analysts surveyed by FactSet. Total sales surged 16% to $5.29 billion, driven primarily by double-digit growth across its core cardiovascular and MedSurg business segments.

The Weight of Future Projections

Despite the strong quarterly finish, investor sentiment soured over the company's forward-looking projections. For the first quarter, Boston Scientific expects adjusted earnings between 78 cents and 80 cents per share, while analysts had been modeling for the top end of that range. The company’s full-year 2026 forecast of $3.43 to $3.49 per share also failed to provide a bullish catalyst, sending shares down 10.3% to $82.22 before the opening bell.

Management anticipates organic sales growth—which strips out the volatility of acquisitions and currency fluctuations—to land between 10% and 11% for the full year. According to the company's report, this outlook reflects a steady but conservative trajectory as it navigates a shifting competitive landscape. Revenue within the cardiovascular division jumped 18% to $3.48 billion, while the MedSurg unit saw a 12% increase to $1.81 billion.

These results come as the company prepares to integrate its recently announced $15 billion acquisition of Penumbra. The deal, reached last month, represents a strategic push into the high-growth vascular thrombectomy market. While the acquisition aims to secure long-term expansion, the immediate market reaction focused on the company’s inability to raise the bar for its near-term earnings targets.